Neurokinin A: The Tachykinin Peptide for Airway, Gut and Inflammatory Research

Neurokinin A (NKA) is a 10-amino-acid tachykinin peptide best known for its preferential activity at the NK2 receptor. Current research interest centres on how the NKA–NK2 pathway influences airway smooth muscle, gastrointestinal motility and inflammatory signalling.

Think of the tachykinin system as a communication network. Different peptides deliver related messages, but each tends to use a preferred “receiver”. Substance P mainly signals through the NK1 receptor, while NKA more strongly activates NK2. The result is a distinct research profile, particularly around smooth muscle contraction.

This article explains where NKA fits, what researchers are investigating and how it differs from substance P.

Research-use notice: Neurokinin A is a research peptide. It is not approved for human use, diagnosis, treatment or self-experimentation. Do not use research chemicals as medicines or supplements. Speak with a qualified clinician before making decisions about any health condition.

What is Neurokinin A?

NKA belongs to the tachykinin family, a group of signalling peptides involved in communication between nerves, smooth muscle and immune-related tissues.

NKA is a decapeptide, meaning it contains ten amino acids. Its structure includes a C-terminal amide group, a feature shared by many tachykinins and important for receptor activity.

The peptide is produced from the TAC1 gene, also known as the preprotachykinin A gene. This is one of the most important points when understanding NKA: it is closely related to substance P because both can be produced from the same gene-derived precursor.

One genetic source, different signalling roles

You can think of TAC1 as a master construction plan. Through alternative processing and splicing, the cell can produce related peptide messengers from that plan.

Depending on the precursor form and tissue, TAC1-derived products can include:

• Substance P
• Neurokinin A
• Related tachykinins such as neuropeptide K and neuropeptide gamma

The peptides may share an origin, but they are not interchangeable. They have different receptor preferences and can produce different biological effects.

The key point: NKA and substance P are family members with a shared molecular background, not identical signals.

NKA and the NK2 receptor

The NK2 receptor, short for neurokinin-2 receptor, is a cell-surface receptor in the tachykinin receptor family. It belongs to a broader class called G protein-coupled receptors, or GPCRs. GPCRs work like cellular doorbells: when the right messenger binds, they trigger a chain of internal signals.

NKA is considered the preferential natural ligand for NK2. In plain English, NKA is one of the most effective tachykinin “keys” for this receptor.

NK2 receptors are found in tissues that contain smooth muscle, including:

• The airways
• The gastrointestinal tract
• Other visceral tissues
• Selected regions of the nervous system

When NKA activates NK2 receptors, the downstream response often involves smooth muscle contraction. This is why researchers focus on the NKA–NK2 axis when studying airway narrowing and intestinal movement.

The receptor is the switch. NKA is one of the signals that flips it.

Airway research: bronchoconstriction and smooth muscle

One of the best-established research areas for NKA is the respiratory system.

The airways contain smooth muscle that can tighten or relax. When this muscle tightens, the airway becomes narrower. This process is called bronchoconstriction.

Researchers study NKA because it can activate NK2 receptors on airway smooth muscle and produce contraction. In laboratory and clinical research settings, NKA has been associated with:

• Airway smooth muscle contraction
• Bronchoconstriction
• Changes in airway responsiveness
• Interaction with sensory nerve signalling
• Investigation of asthma-related pathways

A useful analogy is to picture the airway as a flexible tunnel. The airway lining is the tunnel wall, while the surrounding smooth muscle acts like an adjustable drawstring. Strong NKA–NK2 signalling can pull that drawstring tighter.

This does not mean NKA is a treatment for asthma. In fact, the opposite is important: NKA can contribute to airway narrowing in experimental models. That makes it useful as a research tool for investigating respiratory pathways, not as a self-treatment option.

NKA, NK2 and airway inflammation

Airway biology is not controlled by one pathway. Smooth muscle contraction, mucus production, vascular changes and immune signalling can overlap.

NKA may contribute to neurogenic inflammation, where nerve-derived signals influence inflammatory and vascular responses. However, research often distinguishes the mechanical effects of NK2 activation from the broader inflammatory effects associated with NK1 signalling.

This distinction matters:

• NK2 signalling is strongly associated with direct airway smooth muscle contraction.
• NK1 signalling, driven mainly by substance P, is more closely associated with mucus secretion, vascular permeability and several classic inflammatory responses.
• Both pathways can interact, depending on the tissue and experimental conditions.

The respiratory system is a team sport, not a single-player game. NKA is one important player, but it does not explain every airway response.

Gastrointestinal research: gut motility

The gastrointestinal tract depends on carefully coordinated waves of smooth muscle activity. These waves move food and digestive contents through the system. This process is known as motility.

NKA is relevant to gut research because NK2 receptors are present in intestinal smooth muscle. Activation of this pathway can influence contraction and movement within the gastrointestinal tract.

Researchers investigate NKA in relation to:

• Intestinal smooth muscle contraction
• Peristaltic movement
• Coordination of gut motility
• Communication between enteric nerves and gastrointestinal tissue
• Interactions between neural and inflammatory pathways in the gut

Think of the intestine as a conveyor belt. The belt must move at the right speed: too little movement can slow transit, while excessive or poorly coordinated contraction can create discomfort and dysfunction. NKA is one of the signalling molecules researchers examine when mapping this control system.

NKA is not a digestive supplement, and it should not be used to manage constipation, abdominal pain or inflammatory bowel conditions.

Neurokinin A and substance P: related, but not the same

Because NKA and substance P can originate from the TAC1 gene, they are often discussed together. They also occur in sensory nerve pathways involved in pain signalling and neurogenic inflammation.

However, their preferred receptors help explain their different research profiles.

This is similar to two keys cut from the same keyring. They may look related, but each fits a different lock more effectively.

Pain and neurogenic inflammation

Substance P and NKA are both involved in research into nociception, the nervous system’s detection and processing of potentially harmful stimuli. They are also studied in relation to neurogenic inflammation.

When sensory nerves release tachykinins, nearby blood vessels, smooth muscle and immune-related cells may respond. This creates a bridge between the nervous system and inflammatory biology.

NKA may contribute through NK2-dependent effects, particularly involving smooth muscle. Substance P often has a stronger association with NK1-mediated inflammatory and secretory responses. In living systems, however, these pathways can overlap and influence one another.

The practical research lesson is simple: studying NKA alone may not capture the full tachykinin response. Researchers often consider NKA, substance P, their receptors and the surrounding tissue environment together.

Why researchers study NKA

NKA is valuable as a research subject because it provides a focused way to examine the NK2 pathway.

Research applications may include:

• Airway smooth muscle pharmacology
• Bronchoconstriction and airway hyperresponsiveness models
• Gastrointestinal motility studies
• Tachykinin receptor signalling
• Neurogenic inflammation
• Pain-pathway research
• Testing selective NK2 receptor antagonists
• Comparing NK1 and NK2 contributions to tissue responses

Researchers may also use NKA to test whether a response is receptor-specific. For example, if an NK2 antagonist reduces NKA-induced contraction, that supports the involvement of the NKA–NK2 pathway.

This is how biological mapping works: apply a defined signal, observe the response and use selective tools to identify the receptor or pathway involved.

Product availability and research guidance

WL Australia’s catalogue includes related neuropeptide research products, including Neuropeptide Y, Neuropeptide S, Neuropeptide W and Neurotensin.

At the time of publication, a dedicated Neurokinin A product page was not visible in the indexed WL Australia catalogue. For current stock information, specifications or availability, visit the WL Australia shop or contact the team directly.

For broader reading, explore:

• The complete guide to nootropic peptides
• ARA-290: The nerve repair peptide for neuropathy and pain research
• Mitochondrial Mojo: SS-31 and Humanin

Video placeholder 1: Insert an explainer video showing the tachykinin family, TAC1 processing and the different receptor preferences of substance P and NKA.

Video placeholder 2: Insert a research animation showing NKA–NK2 signalling in airway smooth muscle and gastrointestinal motility.

Safety, regulation and responsible interpretation

NKA research must be approached with the same care as any biologically active signalling molecule.

Remember:

• Research peptides are not automatically approved medicines.
• Do not inject, ingest, inhale or otherwise use NKA for personal experimentation.
• Do not use it to manage asthma, abdominal symptoms, pain or inflammation.
• Airway-active research compounds may be especially hazardous for people with asthma or other respiratory conditions.
• A clinician should review any health concern before you consider a treatment.
• Research findings from cells or animals do not automatically predict human safety or benefit.
• Follow Australian regulatory requirements and the supplier’s stated research-use conditions.

The strongest conclusion is also the simplest: NKA is a focused research tool for understanding tachykinin biology, especially NK2-driven airway and gut smooth muscle signalling. Its relationship with substance P makes the system more interesting, but also more complex.

Research carefully. Interpret cautiously. Keep safety at the centre.